GlassScriptPhysician profile
Mitra Iran Nejad
NPI 1023363223
$7,828.50
in general payments reported to CMS, 2019-2025
13 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,615 · 2020: $736 · 2021: $1,054 · 2022: $1,294 · 2023: $1,852 · 2024: $852 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,129.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $6,638.29 | 2019-2025 | Clareon, Centurion, Argos |
| Johnson & Johnson Surgical Vision, INC. | $299.35 | 2021-2024 | Tecnis Simplicity, Tecnis Iol |
| Dutch Ophthalmic, USA | $166.48 | 2023 | Tissueblue, Eva, Combined Machine |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $149.47 | 2019 | |
| Optos, INC. | $117.12 | 2020 | |
| Rxsight INC | $112.71 | 2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Abbvie INC. | $109.86 | 2022 | |
| Bausch & Lomb Americas INC. | $80.71 | 2023-2024 | Envista Mx60 Iol, Vyzulta, Miebo |
| Oyster Point Pharma, INC. | $37.88 | 2023 | Tyrvaya |
| Glaukos Corporation | $36.13 | 2020-2021 | |
| Carl Zeiss Meditec, INC. | $31.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.29 | 2023 | |
| Sun Pharmaceutical Industries INC. | $17.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitra Nejad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.